Post marketing surveillance included In which phase of drug clinical trial-

## **Core Concept**
Post-marketing surveillance, also known as pharmacovigilance, is the process of monitoring the safety of drugs after they have been marketed. This phase is crucial for identifying rare or long-term adverse effects that may not have been apparent during the earlier phases of clinical trials.

## **Why the Correct Answer is Right**
The correct answer, **Phase IV**, is the post-marketing phase of drug clinical trials. During Phase IV, the drug is administered to a larger population, and its effectiveness and safety are monitored in a real-world setting. This phase helps in detecting rare adverse drug reactions and provides valuable information on the drug's performance in various populations.

## **Why Each Wrong Option is Incorrect**
- **Option A: Phase I** - This is the first phase of testing in human subjects and primarily focuses on assessing the drug's safety, tolerability, pharmacokinetics, and pharmacodynamics in a small group of healthy volunteers or patients.
- **Option B: Phase II** - Conducted on larger groups of patients, Phase II aims to determine the efficacy and side effects of the drug. It is not related to post-marketing surveillance.
- **Option C: Phase III** - This phase involves large-scale trials to confirm the drug's effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the experimental drug to be used safely.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that post-marketing surveillance (Phase IV) is critical for the ongoing safety assessment of drugs. It can lead to the identification of previously unrecognized side effects, and sometimes, these findings can result in restrictions or even withdrawal of the drug from the market.

## **Correct Answer: D. Phase IV**